Ophthalmology has long been one of medicine’s most independent specialties. About 70.4% of ophthalmologists were in private practice, according to the American Medical Association’s 2025 Physician Practice Benchmark Report.
But private equity has still made deep inroads in the last several years, and PE involvement now exceeds 30% in ophthalmology, gastroenterology and dermatology. Although deal volume has cooled since the boom, with fewer than 100 ophthalmology groups transacting in 2025 compared to more than 300 in 2021, according to a VMG Health report, acquirers are now prioritizing high-quality practices in existing markets to build geographic density.
That density can matter as much at the contracting table as in the operating room. Independent ASC leaders have warned that vertically integrated platforms can build narrow networks that “cut out and suffocate competitors in their markets,” Andrew Lovewell, CEO of Columbia (Mo.) Orthopaedic Group, told Becker’s in February.
Bavand Youssefzadeh, DO, a cornea and refractive surgeon and co-founder of Global Lasik and Cataract Institute, an anterior segment practice with offices in Beverly Hills, Woodland Hills and Pasadena, Calif., told Becker’s that consolidation in his market has a specific shape.
“I think all markets in general, but Southern California is a very tough market. There’s a couple really big groups out here who are really cutthroat. Also, they have some VC money behind them, so they’re just buying everybody,” he said.
Those groups’ reach extends beyond acquisitions into managed care contracting.
“But they also monopolize on the HMO plans, the IPAs. So for a private practice like me, I can’t even get on these plans,” he said, explaining that bigger groups often make deals with health plans that exclude other practices’ access.
Dr. Youssefzadeh said patients bear the cost of those arrangements.
“And then they make the patients wait four, six, eight months to get care that they need, and then people get sicker and sicker and sicker,” he said, “And at the end of the day, either they dump the plan and get sent to a university or someone who can’t fix the eyes, or they just get bad care.”
Dr. Youssefzadeh sees the HMO lockout as one piece of a broader shift in who owns eye care, and he is blunt about private equity’s role in it.
“The people that get hurt are the consumers or the patients,” he said. “First and foremost, once you take the owner doctor out of it, the practice is never going to be the same. The quality of medicine is not going to be the same.”
He expects the ownership chain to keep growing.
“When you do that, you flood the market with acquisitions and there’s no more private practice. Then bigger and bigger fish start buying it, and insurance companies get involved, and pharmacies get involved, and then you just have this big conglomerate of people with money making decisions from the doctors to the patients to the insurance companies,” he said.
Recent ophthalmology dealmaking has followed a similar path, with drug distributors buying PE-built platforms. Cencora completed its acquisition of Retina Consultants of America in January 2025, and McKesson agreed a month later to acquire an 80% stake in Prism Vision Holdings for about $850 million. PRISM Vision is now set to acquire Spectrum Vision Partners, a network of more than 50 practices and more than five ASCs, from private equity firm Blue Sea Capital.
Dr. Youssefzadeh doesn’t expect the trend to reverse.
“I can’t imagine it’s ever going to stop because the lobbyists are strong,” he said. “Who’s going to put a stop to this? Because it’s going to ruin medicine. It’s already ruining medicine. It’s just going to make it even worse and worse, and it’s going to drive up costs.”
